ArticleImmunity2023
Intestinal microbiota controls graft-versus-host disease independent of donor-host genetic disparity.
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Trial
- Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect.Nature communications · 2025Trial
- The gut microbiome in graft-versus-host disease: mechanisms of immune modulation and therapeutic approaches.Gut microbes · 2026Review
- Intestinal Epithelial MHC-II at the Interface of Microbiota, Immunity, and Inflammation.International journal of molecular sciences · 2026Review
- The intestinal microbiota as a key modulator of acute graft-versus-host disease.Nature reviews. Cancer · 2026Review
- SPHK1 deficiency promotes intestinal homeostasis by ameliorating ER stress-induced gastrointestinal injury during murine graft-versus-host disease.Science China. Life sciences · 2026Article
- Article
- Metataxonomic Analysis and Fatty Acid Profiling of Feces from Children Undergoing Hematopoietic Stem Cell Transplantation.International journal of molecular sciences · 2026Article
- Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.Blood advances · 2026Article
- Loss of GLP-2R signaling in Glp2rMolecular metabolism · 2026Article
- Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment.Frontiers in immunology · 2026Review
- Biological and technical variability in mouse microbiota analysis and implications for sample size determination.Lab animal · 2026Article
- Intestinal reengineering: Scientific advances in intestinal transplantation.World journal of gastrointestinal surgery · 2025Review
- "The microbiome in graft-versus-host disease: a tale of two ecosystems".Journal of translational medicine · 2025Review
- Cellular therapies for the prevention and treatment of acute graft-versus-host disease.Stem cells (Dayton, Ohio) · 2025Review
- Impact of Liver and Kidney Function on Vitamin D3 Metabolism in Female and Male Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation.International journal of molecular sciences · 2025Article
- Organ-specific microenvironments drive divergent T cell evolution in acute graft-versus-host disease.Science translational medicine · 2025Article
- Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions.Molecular medicine (Cambridge, Mass.) · 2025Review
- Current status, challenges, and integration pathways of biomarker classification systems in graft-versus-host disease: a preliminary exploration.Frontiers in medicine · 2025Review
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 8 institutions in 3 countries.
Motoko KoyamaTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA. Electronic address: mkoyama@fredhutch.org.
Daniel S HippeClinical Research Division, FHCC, Seattle, WA 98109, USA.
Sujatha SrinivasanVaccine and Infectious Disease Division, FHCC, Seattle, WA 98109, USA.
Sean C ProllVaccine and Infectious Disease Division, FHCC, Seattle, WA 98109, USA.
Oriana MiltiadousDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Naisi LiTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA.
Ping ZhangTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA.
Kathleen S EnsbeyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA.
Noah G HoffmanDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Christine R SchmidtTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA.
Albert C YehTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Simone A MinnieTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA.
Susan M StrenkVaccine and Infectious Disease Division, FHCC, Seattle, WA 98109, USA.
Tina L FiedlerVaccine and Infectious Disease Division, FHCC, Seattle, WA 98109, USA.
Namita HattangadyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA.
Jacob KowalskyVaccine and Infectious Disease Division, FHCC, Seattle, WA 98109, USA.
Willian M GradyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Mariapia A Degli-EspostiInfection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; Centre for Experimental Immunology, Lions Eye Institute, Nedlands, WA 6009, Australia.
Antiopi VareliasTransplantation Immunology Laboratory, Cancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Faculty of Medicine, University of Queensland, St Lucia, QLD 4067, Australia.
Andrew D CloustonMolecular and Cellular Pathology, University of Queensland, Brisbane, QLD 4006, Australia.
Marcel R M van den BrinkDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA; Department of Immunology, Sloan Kettering Institute, New York, NY 10065, USA.
Neelendu DeyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Timothy W RandolphClinical Research Division, FHCC, Seattle, WA 98109, USA; Public Health Sciences Division, FHCC, WA 98109, USA.
Kate A MarkeyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98109, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.
David N FredricksVaccine and Infectious Disease Division, FHCC, Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Geoffrey R HillTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98109, USA. Electronic address: grhill@fredhutch.org.
Fred Hutch Cancer Center · USUniversity of Washington · USMemorial Sloan Kettering Cancer Center · USThe University of Queensland · AUCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAInfectious Disease Research Institute · USLions Eye Institute · AUWaianae Coast Comprehensive Health Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTranslational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MT LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1985 to 2023
$59.0MThymic and Peripheral Aspects of T Cell Aging and RejuvenationP01AG052359 · NIA · UNIVERSITY OF ARIZONA · PI JANKO Z. NIKOLICH · 2017 to 2026
$23.5MInterdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7MPreventing GVHD by inhibition of alloantigen presentation in the gutR01HL148164 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL, Motoko Koyama · 2019 to 2026
$6.5MThe role of intestinal microbiota in graft-versus-host diseaseR01CA228308 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Philip L Lorenzi, Marcel R M van den Brink · 2018 to 2026
$5.2MThe role of autophagy gene Atg16L1 in allogeneic hematopoietic stem cell transplantation - Resubmission - 1R01HL123340 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CADWELL, KEN HASHIGIWA, VAN DEN BRINK, MARCEL R M · 2015 to 2022
$5.2MThird-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCTR01HL147584 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI VAN DEN BRINK, MARCEL R M · 2019 to 2022
$2.7MThe role of intestinal microbiota in graft-versus-host diseaseR01CA228358 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VAN DEN BRINK, MARCEL R M · 2018 to 2022
$2.6MHigh-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0MNCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA228308NCI NIH HHS R01 CA228358NCI NIH HHS T32 CA080416NHLBI NIH HHS R01 HL123340NHLBI NIH HHS R01 HL147584NHLBI NIH HHS R01 HL148164NIA NIH HHS P01 AG052359NIH HHS S10 OD028685
Abstract
Acute graft-versus-host disease (aGVHD) remains a major limitation of allogeneic stem cell transplantation (SCT), and severe intestinal manifestation is the major cause of early mortality. Intestinal microbiota control MHC class II (MHC-II) expression by ileal intestinal epithelial cells (IECs) that promote GVHD. Here, we demonstrated that genetically identical mice of differing vendor origins had markedly different intestinal microbiota and ileal MHC-II expression, resulting in discordant GVHD severity. We utilized cohousing and antibiotic treatment to characterize the bacterial taxa positively and negatively associated with MHC-II expression. A large proportion of bacterial MHC-II inducers were vancomycin sensitive, and peri-transplant oral vancomycin administration attenuated CD4
Indexed as
Gastrointestinal MicrobiomeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationAnimalsMiceTransplantation, HomologousVancomycinVancomycinantibioticsgraft-versus-host diseaseGVHDinterferon-γintestinal epithelial cellsMHC class II antigen presentationmicrobiota
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.